Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 15, 2019. The document serves as a transaction notification reporting changes in shareholdings by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions were executed on January 11, 2019, primarily on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions. Key transaction metrics include:
- Instrument Types: Ordinary Shares (19 pence each, ISIN: GB0009252882) and American Depositary Shares (ADSs, ISIN: US37733W1053).
- Transaction Price (Ordinary Shares): GBP 15.3600 per share.
- Transaction Price (ADSs): USD 39.3600 per share.
- Total Volume (Ordinary Shares): 5,836 shares across multiple executives.
- Total Volume (ADSs): 189 shares across multiple executives.
Material Changes
The filing reports an increase in notional interest in GSK securities for ten senior executives. These increases were not open-market purchases but resulted from the re-investment of dividends paid to shareholders on January 10, 2019. The shares were held in the Company's Deferred Annual Bonus Plan or Performance Share Plan. No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with the Securities Exchange Act of 1934.
Important Facts for Investors
- Transaction Nature: All reported transactions were automatic dividend re-investments, not discretionary purchases by executives.
- Executives Involved: Transactions were reported for the CEO (Ms. E. Walmsley), CFO (Mr. S. P. Dingemans), and other senior leaders including the President of Global Vaccines and Global Pharmaceuticals.
- Market Prices: The filings confirm the trading price of Ordinary Shares at GBP 15.36 and ADSs at USD 39.36 on January 11, 2019.
- No Financial Data: Investors should not look to this specific filing for quarterly or annual financial results; it is strictly a transaction notification.